This New Vaccine Could Be A Pandemic Game-Changer … The new CORBEVAX vaccine was produced without significant public funding; the $7 million needed for development was provided by philanthropists.
The world now has a new Covid-19 vaccine in its arsenal, and at a fraction of the cost per dose.
Two years into the Covid-19 pandemic, the world has seen over 314 million infections and over 5.5 million deaths worldwide. Approximately 60% of the world population has received at least one dose of a Covid-19 vaccine. But there is still a glaring and alarming gap in global access to these vaccines. As a virologist who has followed this pandemic closely, I contend that this vaccine inequity should be of grave concern to everyone.
If the world has learned anything from this pandemic, it’s that viruses do not need a passport. And yet approximately 72% of vaccine doses were administered in high- and upper-middle-income countries – and only 1% in low-income countries. Wealthy countries are giving boosters, and even fourth doses, while first and second doses are not available to many worldwide.
